Two-pronged approach Last question during CC below which clearly states both CFO and CMO believe any partnership attempts for either mono or combo therapies could be made independently as Wino suggested many times.
"Okay. There's a one last question from the webcast that we will take is related to combination trials. Would any partnerships in the new combination area depend on the success of the current trial or are they more standalone?
Paul Levesque
Well, thanks for the question. I think that we are convinced that with the changes that we're making now, TH1902 will be successful as is in solo. And that's the reason why it has to go back in the clinic, and we have to continue to collect positive data. Now this being said, is that once that is in the clinic, I think that we will publish additional data on what we have and therefore we will grab additional attention for partnership. So, it's a two-pronged approach, but obviously TH1902 for us is an agent that will actually serve a purpose in the clinic as a solo compound.
Christian, you agree with that, I suppose.
Christian Marsolais
Yeah, absolutely. And in addition, the new data that we have seen, what we just announced and will be presented at AACR are very interesting. When we administer TH1902 in this animal model, we see a significant infiltration of tumor lymphocytes, which means that in that experiment, we use what we called a cold tumor and it looks like TH1902 can turn this cold tumor into a hot tumor, meaning that there would be immune cells infiltration into tumor, which means that in addition, if you add PD-L1 inhibitor, you potentiate the activity of those PD-L1. And this is what we have shown in the animal model and we do believe that this could lead also to very interesting partnership and combination as we move forward with the Phase 1 trial."